Tuesday 1 May 2012: Ludwig Institute for Cancer Research, Melbourne-Austin Branch (LICR) proudly announced today that Director Medical Oncology Unit Professor Jonathan Cebon has been awarded an ‘Established Investigator Award’ and research grant by the Melanoma Research Alliance (MRA). MRA has awarded 22 researchers at leading academic research institutions around the world to develop improved means to prevent, detect and treat deadly skin cancer. Click here to read.

Thursday 26 April, 2012: A brand new, state-of-the-art laboratory that is set to take nuclear medical imaging and cancer research in Melbourne to a whole new level was officially opened at the Austin Hospital. The Positron Emission Tomography (PET) Solid Targetry Laboratory will enable researchers from the Ludwig Institute for Cancer Research (LICR), Austin Health and the Australian Nuclear Science and Technology Organisation (ANSTO) to pursue vital research into new nuclear imaging techniques to benefit patients affected by different types of cancers.

Tuesday 21 February 2012: The Ludwig Institute for Cancer Research (LICR) today announced that the first-in-patient trial with the monoclonal antibody ABT-806i is underway at Austin Health in Melbourne. ABT-806i was created from the monoclonal antibody mAb806, which was generated and characterised by LICR, and later successfully licensed to Abbott through Life Science Pharmaceuticals (LSP).

January 2012: Ludwig Institute for Cancer Research's (LICR) Dr Andreas Behren has been granted funding of $180,000 over two years from Cure Cancer Australia Foundation's YI Postdoctoral Fellowship 2012/2013 for his project on the identification and targeting of melanoma cells undergoing EMT to interfere with metastasis and chemoresistance.

December 2011: The Ludwig Istitute for Cancer Research receives funding from Cancer Australia and Cancer Council Victoria 2011. Click to read more

Tuesday 29 November 2011: The Ludwig Institute for Cancer Research (LICR) has secured a $2million grant from the Australian Cancer Research Foundation (ACRF) that will assist in establishing a state-of-the-art ACRF Centre for Translational Cancer Therapeutics and Imaging benefiting Australian cancer sufferers.

The second Ludwig Institute for Cancer Research Translational Oncology Conference and was held at the Park Hyatt, Melbourne 24th-26th October 2011. Attracting over 125 delegates the final program was a great success. The next conference is planned for 2013. The final program and abstracts are available at http://www.licrconference.org/program-with-abstracts/.

Wednesday 2 November 2011: Ludwig Institute for Cancer Research (LICR) has secured a grant from the Prostate Cancer Foundation of Australia (PCFA) to examine novel ways of assessing prostate cancer. Associate Professor Ian Davis, head of the LICR Uro Oncology Laboratory and senior oncologist in the joint LICR-Austin Oncology Unit, said the project is part of an ongoing research program to evaluate how useful PET scanning is in the management of prostate cancer.

Friday 30 September 2011: Professor Andrew Scott, Director, Ludwig Institute for Cancer Research, Melbourne-Austin and Nuclear medicine expert, has been reappointed to the Australian Nuclear Science and Technology Organisation (ANSTO) Board for another five years. Innovation Minister Senator Kim Carr said Professor Scott's combined medical expertise and previous experience with boards has been invaluable during his four year term on the ANSTO Board. "Professor Scott's background in nuclear medicine is crucial to the Board particularly given ANSTO's focus on the public benefits and commercial opportunities in the area of medical nuclear science," Senator Carr said.

Wednesday 23 March 2011: KaloBios has licensed this target from the Australian team who discovered EphA3, an onco-fetal protein that is expressed in a range of cancers, including hematologic malignancies and possibly on leukemic stem cells. The team of Australian collaborators, including Dr.Martin Lackmann of Monash University, Melbourne; Dr. Andrew Boyd of Queensland Institute of Medical Research and the University of Queensland, Brisbane, who originally isolated the KB004 precursor monoclonal antibody, IIIA4; and Dr. Andrew Scott of Ludwig Institute for Cancer Research, Melbourne, realized the potential of EphA3 as an anti-cancer target and, in a series of animal studies, evaluated the IIIA4 antibody as an anti-cancer agent.

Wednesday 15 September 2010: The Australian Nuclear Science and Technology Organisation (ANSTO) will invest $1.5 million to construct a state-of-the-art laboratory at Austin Health's Centre for PET. "This project will give medical researchers access to the use of long-lived isotopes that we cannot make with a nuclear reactor" CEO of ANSTO, Dr Paterson said. The ANSTO investment will support Austin Health and the Ludwig Institute for Cancer Research to continue conducting cutting-edge clinical cancer research and boost Victoria's reputation as a national centre of medical research excellence.

Tuesday 7 September 2010: Innovation Minister Gavin Jennings today announced $25.7 million in State Government funding to 13 major Victorian research institutes including $ 1.426 million to Ludwig Institute for Cancer Research (LICR) to help them meet the indirect costs of their life-saving research. Visiting LICR at the Austin Hospital to launch a clinical trial for a potential new treatment for kidney cancer, Mr Jennings said the funding helped medical institutes direct their research funding to where it counts the most - medical research.

February 2010: The SCImago Institutions Rankings (SIR) 2009 World Report lists the Ludwig Institute for Cancer Research in the top 10 institutions in the world for average scientific impact of publication output (CXD) from 2003 to 2009.

Friday 20 March 2009: The Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd ("ANZUP") was launched today in Sydney. Initiated by A/Prof Ian Davis, ANZUP was formed to meet a need for greater collaboration within the Australian medical community on research and clinical trials, particularly for urogenital cancers (prostate, testicular, kidney and bladder).

Thursday January 1, 2009. Investigators from the Ludwig Institute for Cancer Research (LICR) Melbourne Center reported today in the journal The Prostate that a potential new reagent could treat prostate tumors with greater specificity and reduced toxicity than many currently used therapies.

Monday 17 November 2008, The international Ludwig Institute for Cancer Research (LICR) announced today that one of its spin-off companies, Life Science Pharmaceuticals, has licensed its lead cancer therapy candidate to pharmaceutical company Abbott.

Friday 15 August 2008, Investigators from the Melbourne Center of the international Ludwig Institute For Cancer Research (LICR) and Pacific Edge Biotchnology Ltd today reported that they have developed a test to predict whether a patient will progress rapidly from Stage III melanoma to metastatic Stage IV cancer and death.

July 16, 2008. The Melanoma Research Alliance (MRA), a new public charity based in Washington D.C., USA, recently awarded 8 million USD in grants to individual scientist and research teams to support innovative melanoma research worldwide. An international team headed by Prof. Jonathan Cebon (LICR Melbourne-Austin Branch) received one of six Team Science Awards of 1million USD. The award will be used to explore immune targeting of melanoma stem cells. The team also includes Drs. Otavia Caballero (LICR New York Branch), Winston Hide (LICR Affiliate, South African National Bioinformatics Institute, South Africa), and Michael Berridge (Malaghan Institute for Medical Research, New Zealand)

Friday 8 June 2007, The LICR Brain Cancer Initiative held its first meeting in New York on June 8th and 9th. LICR has a strong history in glioblastoma research, in particular, and there was great enthusiasm among the 34 participants from six Branches, the Melbourne Center, the Ludwig Center at Johns Hopkins and two Affiliates.

The Time magazine issue - 'The Most Influential People in the World' May 14th, 2007 -included Mr. Ludwig in it's list of "Power Givers - Philanthropists of Yore.' The list of 11 such philanthropists also included Messrs. John Pierpont Morgan, John D. Rockefeller, Andrew Carnegie, Alfred Nobel, Cecil Rhodes and Joseph Pulitzer.

Friday 9 June 2006, Dr Ken Pang, from the Ludwig Institute For Cancer Research in Heidelberg, whose research into the role of "junk DNA" reveals that it may in fact be essential in helping us understand how the human genome works, and promises to significantly influence the future practice of medicine.

Monday 5 June 2006, The Ludwig Institute For Cancer Research (LICR) and Life Science Pharmaceuticals (LSP) today announced the results of the first clinical trial of monoclonal antibody (mAb) 806, which demonstrate that 806 specifically targets epidermal growth factor receptor (EGFR) on a wide range of tumor types but has no uptake by normal tissues. This result is markedly different to other mAbs, which target wild-type (wt) EGFR on normal tissues.

Monday 5 June 2006, London, UK & New York, US-GlaxoSmithKline (NYSE and LSE: GSK) and the international Ludwig Institute For Cancer Research (LICR) today announce they have entered into an agreement whereby GSK has licensed a substantial portfolio of tumor-specific antigens from LICR. The licensing agreement follows a long-standing collaboration between both parties on GSK's investigational MAGE-A3 Antigen Specific Cancer Immunotherapeutic (ASCI) in Non-Small Cell Lung Cancer (NSCLC).

Sunday 30 April 2006, (Melbourne, New York, Helsinki) - The Ludwig Institute For Cancer Research ("LICR") together with Circadian Technologies Limited (ASX: CIR) and Licentia Ltd, the commercial arm of the University of Helsinki, has announced the formation of a new company, Vegenics Ltd. Vegenics will develop and commercialise LICR and Licentia intellectual property and technology around the inhibition of two vascular endothelial growth factors (VEGFs) and the VEGF receptor-3, molecules required for angiogenesis and lymphangiogenesis, which allow tumors to grow and cancer to spread. The cancer therapy, Avastin®, inhibits one member of the VEGF family and in 2005 earned Genentech ~US$1.1 billion.